Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a ...

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion-mutated NSCLC, ...

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically different treatment approach for patients with bladder cancer.

Hardeep Phull, MD, director of oncology at Palomar Health, discusses the value of virtual health care and telehealth for both ...

During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ...

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in ...

Neoadjuvant darovasertib elicited strong antitumor activity, reduced simulated radiation doses, and lowered the risk of ...

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent ...

Promising results emerge from a clinical trial combining IDE397 and Trodelvy for treating MTAP-deleted urothelial cancer, ...

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover ...

BioAtla's ozuriftamab vedotin advances to phase 3 trials for HPV-positive oropharyngeal cancer, aiming for accelerated FDA ...